Phase 2RecruitingPriority 2 · High priorityNCT06698822

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

Plain-language summary

This Phase 2 trial is studying tofacitinib 2% cream for people with cutaneous T-cell lymphoma (skin lymphoma). The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.

Who can join (key eligibility)

Age 18 Years or older
Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

tofacitinib 2% cream (DRUG): Given topical

Drugs / treatments: tofacitinib 2% cream
Treatment length: Ask the trial team for details
Visit frequency: Ask the trial team for details

TrialCompass — Clinical Trial Summary

A Phase 2 Trial to Assess Safety and Efficacy of Tofacitinib 2% Cream in the Treatment of Cutaneous T-cell Lymphoma (CTCL), Stages IA, IB, and IIA

NCT06698822

Phase: Phase 2 | Status: Recruiting | Priority: High

Plain-language summary

Who can join

Age 18 Years or older
Must be well enough for treatment (adequate performance status)

What's being tested

tofacitinib 2% cream (DRUG): Given topical

Drugs / treatments: tofacitinib 2% cream

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 20 patients

Primary endpoint: Safety and adverse events (AE's)

Ages: 18 Years to —

Start date: 2025-03-10 | Est. completion: 2026-10-19

Locations

1 US sites · 1 total

Texas

Contact

Julia Dai, MD | jdai6@mdanderson.org | 713-515-7961

Sponsor: M.D. Anderson Cancer Center (OTHER)

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT06698822

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.